In a nutshell This phase 2 clinical trial will test the effectiveness of merestinib in non-small cell lung cancer patients with a mutation in the MET protein. The primary outcome will be measured by the overall response to the treatment. This study is being conducted in Boston, Massachusetts. The details Merestinib is an inhibitor of the C-Met...
Read More
In a nutshell The aim of this study was to examine the effect of preventative fungal treatment in acute leukemia patients with different risk factors. Researchers identified a number of risk factors that can increase the incidence of a severe fungal infection after chemotherapy. Preventative fungal treatment for patients undergoing primary chemotherapy...
Read MoreIn a nutshell This phase 1 clinical trial will test the safety and effectiveness of AMV564 in treating relapsed or refractory (unresponsive to treatment) acute myeloid leukemia (AML). The primary outcome will be measured by adverse (negative) side effects and remission rate. The study is being conducted in Saint Louis, Missouri, New York City, and...
Read More
In a nutshell This phase 2 clinical trial will test the effectiveness of bendamustine (Treanda) and rituximab (Rituxan) induction therapy followed by rituximab and lenalidomide (Revlimid) maintenance therapy in patients with previously untreated chronic lymphocytic leukemia (CLL). The primary outcome will be measured by the time to disease progression....
Read MoreIn a nutshell The authors aimed to determine the effects of yoga on fatigue, erectile dysfunction, urinary problems and quality of life (QoL) in men undergoing radiation therapy for prostate cancer. The authors concluded that yoga twice-weekly during external beam radiation therapy (EBRT) significantly reduced pre-existing and radiation-related...
Read MoreIn a nutshell This study aimed to investigate the influence of the time of starting adjuvant chemotherapy on survival outcomes in different types of breast cancer. This study concluded that more aggressive breast cancers require early adjuvant chemotherapy. Some background Surgery to remove the tumor is a commonly used treatment method for...
Read More
In a nutshell This study examined the effect of age on treatment response to imatinib (Gleevac) for chronic myeloid leukemia (CML). Researchers reported the best clinical outcomes in patients aged between 45 and 65 years. Some background Treatment response for CML is often measured based on patients showing less abnormal chromosomes (cytogenetic...
Read More
In a nutshell This study aimed to investigate the adverse events of inotuzumab ozogamicin (Besponsa) for treatment of relapsed or refractory acute lymphoblastic leukaemia. This study concluded that inotuzumab ozogamicin leads to increased liver damage when compared to standard therapy. Some background Acute lymphoblastic leukaemia (ALL) occurs...
Read More
In a nutshell This study looks at the outcomes for patients over 80 years old who have diffuse large B-cell lymphoma. The study concluded that patients over 80 had significantly better outcomes when treated with rituximab and anthracycline-based chemotherapy, such as the R-CHOP treatment. Some background Diffuse large B-cell lymphoma (DLBCL)...
Read More
In a nutshell This study reviewed evidence on how to categorize older multiple myeloma patients. Some background Advances in treatment approaches have improved response rates and survival for multiple myeloma patients. These typically involve combining immunotherapies, such as lenalidomide (Revlimid), with proteasome inhibitors, such as bortezomib...
Read More
In a nutshell The authors aimed to determine the benefit of robot-assisted radical prostatectomy (RARP) compared to retro-pubic radical prostatectomy (RRP) in reducing biochemical recurrence in men with prostate cancer. The authors concluded that RARP compared to RRP improved positive surgical margins (PSM) and biochemical recurrence. Some...
Read More
In a nutshell This study analyzed the results of multiple studies to examine the effect of bortezomib (Velcade) on cardiac risk (heart health) in multiple myeloma. Results showed no effect on cardiac risk with bortezomib-based treatment. The incidence of cardiac events was low across all treatment groups. Some background Many multiple myeloma...
Read More
